JSPR Investors Should Contact Robbins LLP Regarding the Upcoming Lead Plaintiff Deadline in the Jasper Therapeutics, Inc. Class Action

Jasper’s stock fell 55% after disclosures that it lacked adequate controls over third-party manufacturers, misstating its compliance and operations.......

Read Full Article →